Menu Search
Equities

MicroPort NeuroScientic Corp

2172:HKG.HS

MicroPort NeuroScientic Corp

Actions
  • Price (HKD)10.78
  • Today's Change0.81 / 8.12%
  • Shares traded822.37k
  • 1 Year change-9.56%
  • Beta--
Data delayed at least 15 minutes, as of Oct 07 2024 04:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MicroPort NeuroScientic Corp is an investment holding company mainly engaged in research, development, and production of neuro-interventional medical devices. The Company's product portfolio covers three major areas of cerebrovascular diseases, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke. The Company provides integrated solutions for patients and doctors with cerebrovascular diseases, including promotion and education regarding the surgical methods and products, recommendations for treatment options, training on surgery and surgical devices, clinical support and postoperative follow-ups. The Company's main products include Tubridge Flow-diverting Stent, Fastrack Microcatheter System, WILLIS Intracranial Stent Graft, and others.

  • Revenue in HKD (TTM)857.03m
  • Net income in HKD248.94m
  • Incorporated2020
  • Employees534.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.